News & Media
|Hemostemix Appoints Hardean E. Achneck, M.D. as Chief Medical Officer|
|Mar 25 2016 -
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE: HEM) (OTCQX: HMTXF), a clinical-stage autologous cell therapy company, announced today the promotion of Hardean E. Achneck, M.D., to the position of Chief Medical Officer.
As Chief Medical Officer, Dr. Achneck will lead and implement the company's multinational clinical research programs and oversee all medical affairs activities. "I am very pleased that Dr. Achneck has assumed this important position," said Dr. Elmar Burchardt, President and CEO of Hemostemix. "He has substantial experience with our clinical programs. His deep knowledge of regulatory affairs and cardiovascular medicine, combined with his proven success in leading global teams, will continue to ensure that our clinical trials are conducted according to the highest standards."
Dr. Achneck is a graduate of Yale College and the Yale School of Medicine. He was formerly an Assistant Professor of Surgery and Pathology at the Duke University School of Medicine and Cardiovascular and Metabolic Disorders at Duke-National University of Singapore, Singapore. Dr. Achneck brings over a decade of clinical research experience across various therapeutic areas to the position of Chief Medical Officer. Prior to this promotion, he served Hemostemix as Vice President of Clinical Research and Operations. In that role, he was spearheading the implementation and enhancement of Hemostemix's international, multicenter, phase 2 clinical trial of ACP-01, its lead product for critical limb ischemia. He also coordinated successful regulatory submissions in Canada, South Africa and the United States.
"I am excited to lead Hemostemix's clinical programs," said Dr. Achneck. "Within the last year, we successfully obtained IND clearance from the FDA and initiated the expansion of our clinical trial into the U.S. Adding these new sites will move us toward our interim analysis. I am sure this will open up tremendous opportunities for Hemostemix. As we progress in this important field, we will always be guided by the principles of evidence-based medicine. We will continue to prioritize safety in our ongoing clinical trial and future initiatives."
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, phase 2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase 2 trial targets a participant's diseased tissue with proprietary cells grown from his or her blood that are capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase 2 trial at four sites in South Africa and two sites in Canada. The Company recently received FDA clearance to commence clinical trials in the United States.
Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.